Merck ESMO 2026
Biotech

Merck ends Sutro-partnered IL-2 drug in ‘routine prioritization’

Merck & Co. has called time on a Sutro Biopharma-partnered IL-2 agonist that was being tested for solid tumors.
James Waldron Nov 6, 2026 4:20am
NVS

Novartis’ Lp(a) wipeout casts shadow over Amgen, Lilly programs

Nov 7, 2026 9:50am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Novo saying goodbye to longtime finance chief—Chutes & Ladders

Nov 6, 2026 10:12am
Podcast
Dark blue background with stylized DNA strands and data particles evoking a scientific or biotech theme The text reads T

There's more than one way to build a biotech

Nov 6, 2026 10:02am
T-cells cancer cells CAR-T lymphocytes

Generate sees ‘huge opportunity’ using Claude to improve CAR-Ts

Nov 6, 2026 10:02am
Moderna

Moderna’s norovirus vaccine plans in limbo in wake of ph. 3 miss

Nov 6, 2026 9:51am
More News

Rezera revs up for $181M IPO to fund NLRP3 inhibitor ph. 3 trial

Nov 5, 2026 10:15am

MetaVia’s GLP-1 sheds liver fat and body weight in phase 1

Nov 5, 2026 9:52am
Fierce Pharma

AZ’s reported $10B offer for Rhythm fuels talks of a bidding war

Nov 5, 2026 9:36am

Agios shedding 100 R&D roles ahead of hoped-for SCD approval

Nov 5, 2026 8:40am